From Proteopedia
(Difference between revisions)
proteopedia linkproteopedia link
|
|
| Line 1: |
Line 1: |
| - | [[Image:1u21.gif|left|200px]] | + | {{Seed}} |
| | + | [[Image:1u21.png|left|200px]] |
| | | | |
| | <!-- | | <!-- |
| Line 9: |
Line 10: |
| | {{STRUCTURE_1u21| PDB=1u21 | SCENE= }} | | {{STRUCTURE_1u21| PDB=1u21 | SCENE= }} |
| | | | |
| - | '''transthyretin with tethered inhibitor on one monomer.'''
| + | ===transthyretin with tethered inhibitor on one monomer.=== |
| | | | |
| | | | |
| - | ==Overview==
| + | <!-- |
| - | Protein native state stabilization imposed by small molecule binding is an attractive strategy to prevent the misfolding and misassembly processes associated with amyloid diseases. Transthyretin (TTR) amyloidogenesis requires rate-limiting tetramer dissociation before misassembly of a partially denatured monomer ensues. Selective stabilization of the native TTR tetramer over the dissociative transition state by small molecule binding to both thyroxine binding sites raises the kinetic barrier of tetramer dissociation, preventing amyloidogenesis. Assessing the amyloidogenicity of a TTR tetramer having only one amyloidogenesis inhibitor (I) bound is challenging because the two small molecule binding constants are generally not distinct enough to allow for the exclusive formation of TTR.I in solution to the exclusion of TTR.I(2) and unliganded TTR. Herein, we report a method to tether one fibril formation inhibitor to TTR by disulfide bond formation. Occupancy of only one of the two thyroxine binding sites is sufficient to inhibit tetramer dissociation in 6.0 M urea and amyloidogenesis under acidic conditions by imposing kinetic stabilization on the entire tetramer. The sufficiency of single occupancy for stabilizing the native state of TTR provides the incentive to search for compounds displaying striking negative binding cooperativity (e.g., K(d1) in nanomolar range and K(d2) in the micromolar to millimolar range), enabling lower doses of inhibitor to be employed in the clinic, mitigating potential side effects.
| + | The line below this paragraph, {{ABSTRACT_PUBMED_15826192}}, adds the Publication Abstract to the page |
| | + | (as it appears on PubMed at http://www.pubmed.gov), where 15826192 is the PubMed ID number. |
| | + | --> |
| | + | {{ABSTRACT_PUBMED_15826192}} |
| | | | |
| | ==About this Structure== | | ==About this Structure== |
| Line 30: |
Line 34: |
| | [[Category: Amyloid]] | | [[Category: Amyloid]] |
| | [[Category: Transthyretin]] | | [[Category: Transthyretin]] |
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 10:39:36 2008'' | + | |
| | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 23:38:14 2008'' |
Revision as of 20:38, 28 July 2008
Template:STRUCTURE 1u21
transthyretin with tethered inhibitor on one monomer.
Template:ABSTRACT PUBMED 15826192
About this Structure
1U21 is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.
Reference
Kinetic stabilization of an oligomeric protein by a single ligand binding event., Wiseman RL, Johnson SM, Kelker MS, Foss T, Wilson IA, Kelly JW, J Am Chem Soc. 2005 Apr 20;127(15):5540-51. PMID:15826192
Page seeded by OCA on Mon Jul 28 23:38:14 2008
